Review





Similar Products

polyunsaturated fatty acids (pufas)  (Koppers Inc)
90
Koppers Inc polyunsaturated fatty acids (pufas)
Polyunsaturated Fatty Acids (Pufas), supplied by Koppers Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pufa+fatty+acids/10__1530_slash_raf___24___0056-191-9-24?v=Koppers+Inc
Average 90 stars, based on 1 article reviews
polyunsaturated fatty acids (pufas) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
diet enriched in polyunsaturated fatty acids pufa  (Dyets Inc)
90
Dyets Inc diet enriched in polyunsaturated fatty acids pufa
Effects of NT‐0796, semaglutide, or combinations in mice with DIO switched to a <t>PUFA</t> diet. Mice with DIO fed a HFD were dosed therapeutically with NT‐0796 (100 mg/kg, po, tid), semaglutide (0.005 mg/kg, sc, q.d), or a combination from day 0 to 28. On day 29, diet was switched to a PUFA diet, and the respective treatment continued (over days 29–56). An additional group of mice served as calorie‐restricted controls, body weight of which were maintained as closely to NT‐0796‐dosed mice as possible by controlling the degree of calorie restriction throughout the experiment. (A) Experimental schematic. (B) Percentage body weight change over time. An overnight fast into day 55 (dashed line) was performed for assessment of further exploratory endpoints. (C) Body weight over time. (D) Perirenal, (E) inguinal, (F) epididymal, and (G) total fat mass was assessed at study end (day 56). (H) Average daily food intake and (I) average daily calorie (kilocalories) intake during PUFA diet exposure (days 29–56). (J) Plasma IL‐1RA levels at study end (day 56). Data are expressed as mean ± SEM or as box and whisker plots and analyzed by one‐ or two‐way ANOVA with Tukey multiple comparisons test and significance calculated using GraphPad Prism version 10.2.2. **** p < 0.0001; *** p < 0.001; ** p < 0.01; and * p < 0.05. DIO, diet‐induced obesity; HFD, high‐fat diet; IL‐1RA, interleukin‐1 receptor antagonist; po, orally; PUFA, <t>polyunsaturated</t> fatty acid; qd, 1 time/day; sc, subcutaneously; tid, 3 times/day.
Diet Enriched In Polyunsaturated Fatty Acids Pufa, supplied by Dyets Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pufa+fatty+acids/pmc12210099-31-9-18?v=Dyets+Inc
Average 90 stars, based on 1 article reviews
diet enriched in polyunsaturated fatty acids pufa - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
pufa fatty acid  (Schmid GmbH)
90
Schmid GmbH pufa fatty acid
Effects of NT‐0796, semaglutide, or combinations in mice with DIO switched to a <t>PUFA</t> diet. Mice with DIO fed a HFD were dosed therapeutically with NT‐0796 (100 mg/kg, po, tid), semaglutide (0.005 mg/kg, sc, q.d), or a combination from day 0 to 28. On day 29, diet was switched to a PUFA diet, and the respective treatment continued (over days 29–56). An additional group of mice served as calorie‐restricted controls, body weight of which were maintained as closely to NT‐0796‐dosed mice as possible by controlling the degree of calorie restriction throughout the experiment. (A) Experimental schematic. (B) Percentage body weight change over time. An overnight fast into day 55 (dashed line) was performed for assessment of further exploratory endpoints. (C) Body weight over time. (D) Perirenal, (E) inguinal, (F) epididymal, and (G) total fat mass was assessed at study end (day 56). (H) Average daily food intake and (I) average daily calorie (kilocalories) intake during PUFA diet exposure (days 29–56). (J) Plasma IL‐1RA levels at study end (day 56). Data are expressed as mean ± SEM or as box and whisker plots and analyzed by one‐ or two‐way ANOVA with Tukey multiple comparisons test and significance calculated using GraphPad Prism version 10.2.2. **** p < 0.0001; *** p < 0.001; ** p < 0.01; and * p < 0.05. DIO, diet‐induced obesity; HFD, high‐fat diet; IL‐1RA, interleukin‐1 receptor antagonist; po, orally; PUFA, <t>polyunsaturated</t> fatty acid; qd, 1 time/day; sc, subcutaneously; tid, 3 times/day.
Pufa Fatty Acid, supplied by Schmid GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pufa+fatty+acids/10__1007_slash_s10811___025___03452___w-315-18-31?v=Schmid+GmbH
Average 90 stars, based on 1 article reviews
pufa fatty acid - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
anti-inflammatory effect of a diet rich in polyunsaturated fatty acids (pufa)  (DuPont de Nemours)
90
DuPont de Nemours anti-inflammatory effect of a diet rich in polyunsaturated fatty acids (pufa)
Effects of NT‐0796, semaglutide, or combinations in mice with DIO switched to a <t>PUFA</t> diet. Mice with DIO fed a HFD were dosed therapeutically with NT‐0796 (100 mg/kg, po, tid), semaglutide (0.005 mg/kg, sc, q.d), or a combination from day 0 to 28. On day 29, diet was switched to a PUFA diet, and the respective treatment continued (over days 29–56). An additional group of mice served as calorie‐restricted controls, body weight of which were maintained as closely to NT‐0796‐dosed mice as possible by controlling the degree of calorie restriction throughout the experiment. (A) Experimental schematic. (B) Percentage body weight change over time. An overnight fast into day 55 (dashed line) was performed for assessment of further exploratory endpoints. (C) Body weight over time. (D) Perirenal, (E) inguinal, (F) epididymal, and (G) total fat mass was assessed at study end (day 56). (H) Average daily food intake and (I) average daily calorie (kilocalories) intake during PUFA diet exposure (days 29–56). (J) Plasma IL‐1RA levels at study end (day 56). Data are expressed as mean ± SEM or as box and whisker plots and analyzed by one‐ or two‐way ANOVA with Tukey multiple comparisons test and significance calculated using GraphPad Prism version 10.2.2. **** p < 0.0001; *** p < 0.001; ** p < 0.01; and * p < 0.05. DIO, diet‐induced obesity; HFD, high‐fat diet; IL‐1RA, interleukin‐1 receptor antagonist; po, orally; PUFA, <t>polyunsaturated</t> fatty acid; qd, 1 time/day; sc, subcutaneously; tid, 3 times/day.
Anti Inflammatory Effect Of A Diet Rich In Polyunsaturated Fatty Acids (Pufa), supplied by DuPont de Nemours, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pufa+fatty+acids/pm39615158-33-3-25?v=DuPont+de+Nemours
Average 90 stars, based on 1 article reviews
anti-inflammatory effect of a diet rich in polyunsaturated fatty acids (pufa) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
omega-3 polyunsaturated fatty acids (pufas)  (Turck Inc)
90
Turck Inc omega-3 polyunsaturated fatty acids (pufas)
Effects of NT‐0796, semaglutide, or combinations in mice with DIO switched to a <t>PUFA</t> diet. Mice with DIO fed a HFD were dosed therapeutically with NT‐0796 (100 mg/kg, po, tid), semaglutide (0.005 mg/kg, sc, q.d), or a combination from day 0 to 28. On day 29, diet was switched to a PUFA diet, and the respective treatment continued (over days 29–56). An additional group of mice served as calorie‐restricted controls, body weight of which were maintained as closely to NT‐0796‐dosed mice as possible by controlling the degree of calorie restriction throughout the experiment. (A) Experimental schematic. (B) Percentage body weight change over time. An overnight fast into day 55 (dashed line) was performed for assessment of further exploratory endpoints. (C) Body weight over time. (D) Perirenal, (E) inguinal, (F) epididymal, and (G) total fat mass was assessed at study end (day 56). (H) Average daily food intake and (I) average daily calorie (kilocalories) intake during PUFA diet exposure (days 29–56). (J) Plasma IL‐1RA levels at study end (day 56). Data are expressed as mean ± SEM or as box and whisker plots and analyzed by one‐ or two‐way ANOVA with Tukey multiple comparisons test and significance calculated using GraphPad Prism version 10.2.2. **** p < 0.0001; *** p < 0.001; ** p < 0.01; and * p < 0.05. DIO, diet‐induced obesity; HFD, high‐fat diet; IL‐1RA, interleukin‐1 receptor antagonist; po, orally; PUFA, <t>polyunsaturated</t> fatty acid; qd, 1 time/day; sc, subcutaneously; tid, 3 times/day.
Omega 3 Polyunsaturated Fatty Acids (Pufas), supplied by Turck Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pufa+fatty+acids/pm39082745-27-57-59?v=Turck+Inc
Average 90 stars, based on 1 article reviews
omega-3 polyunsaturated fatty acids (pufas) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
fatty acid (fa) content (mufa and pufa)  (Bioactive Ingredients)
90
Bioactive Ingredients fatty acid (fa) content (mufa and pufa)
Effects of NT‐0796, semaglutide, or combinations in mice with DIO switched to a <t>PUFA</t> diet. Mice with DIO fed a HFD were dosed therapeutically with NT‐0796 (100 mg/kg, po, tid), semaglutide (0.005 mg/kg, sc, q.d), or a combination from day 0 to 28. On day 29, diet was switched to a PUFA diet, and the respective treatment continued (over days 29–56). An additional group of mice served as calorie‐restricted controls, body weight of which were maintained as closely to NT‐0796‐dosed mice as possible by controlling the degree of calorie restriction throughout the experiment. (A) Experimental schematic. (B) Percentage body weight change over time. An overnight fast into day 55 (dashed line) was performed for assessment of further exploratory endpoints. (C) Body weight over time. (D) Perirenal, (E) inguinal, (F) epididymal, and (G) total fat mass was assessed at study end (day 56). (H) Average daily food intake and (I) average daily calorie (kilocalories) intake during PUFA diet exposure (days 29–56). (J) Plasma IL‐1RA levels at study end (day 56). Data are expressed as mean ± SEM or as box and whisker plots and analyzed by one‐ or two‐way ANOVA with Tukey multiple comparisons test and significance calculated using GraphPad Prism version 10.2.2. **** p < 0.0001; *** p < 0.001; ** p < 0.01; and * p < 0.05. DIO, diet‐induced obesity; HFD, high‐fat diet; IL‐1RA, interleukin‐1 receptor antagonist; po, orally; PUFA, <t>polyunsaturated</t> fatty acid; qd, 1 time/day; sc, subcutaneously; tid, 3 times/day.
Fatty Acid (Fa) Content (Mufa And Pufa), supplied by Bioactive Ingredients, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pufa+fatty+acids/pmc11595550-47-6-2?v=Bioactive+Ingredients
Average 90 stars, based on 1 article reviews
fatty acid (fa) content (mufa and pufa) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
fatty acid standards pufa no.2  (Millipore)
90
Millipore fatty acid standards pufa no.2
Effects of NT‐0796, semaglutide, or combinations in mice with DIO switched to a <t>PUFA</t> diet. Mice with DIO fed a HFD were dosed therapeutically with NT‐0796 (100 mg/kg, po, tid), semaglutide (0.005 mg/kg, sc, q.d), or a combination from day 0 to 28. On day 29, diet was switched to a PUFA diet, and the respective treatment continued (over days 29–56). An additional group of mice served as calorie‐restricted controls, body weight of which were maintained as closely to NT‐0796‐dosed mice as possible by controlling the degree of calorie restriction throughout the experiment. (A) Experimental schematic. (B) Percentage body weight change over time. An overnight fast into day 55 (dashed line) was performed for assessment of further exploratory endpoints. (C) Body weight over time. (D) Perirenal, (E) inguinal, (F) epididymal, and (G) total fat mass was assessed at study end (day 56). (H) Average daily food intake and (I) average daily calorie (kilocalories) intake during PUFA diet exposure (days 29–56). (J) Plasma IL‐1RA levels at study end (day 56). Data are expressed as mean ± SEM or as box and whisker plots and analyzed by one‐ or two‐way ANOVA with Tukey multiple comparisons test and significance calculated using GraphPad Prism version 10.2.2. **** p < 0.0001; *** p < 0.001; ** p < 0.01; and * p < 0.05. DIO, diet‐induced obesity; HFD, high‐fat diet; IL‐1RA, interleukin‐1 receptor antagonist; po, orally; PUFA, <t>polyunsaturated</t> fatty acid; qd, 1 time/day; sc, subcutaneously; tid, 3 times/day.
Fatty Acid Standards Pufa No.2, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pufa+fatty+acids/pmc11647404-203-10-16?v=Millipore
Average 90 stars, based on 1 article reviews
fatty acid standards pufa no.2 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
polyunsaturated fatty acids pufa-3  (Millipore)
90
Millipore polyunsaturated fatty acids pufa-3
Effects of NT‐0796, semaglutide, or combinations in mice with DIO switched to a <t>PUFA</t> diet. Mice with DIO fed a HFD were dosed therapeutically with NT‐0796 (100 mg/kg, po, tid), semaglutide (0.005 mg/kg, sc, q.d), or a combination from day 0 to 28. On day 29, diet was switched to a PUFA diet, and the respective treatment continued (over days 29–56). An additional group of mice served as calorie‐restricted controls, body weight of which were maintained as closely to NT‐0796‐dosed mice as possible by controlling the degree of calorie restriction throughout the experiment. (A) Experimental schematic. (B) Percentage body weight change over time. An overnight fast into day 55 (dashed line) was performed for assessment of further exploratory endpoints. (C) Body weight over time. (D) Perirenal, (E) inguinal, (F) epididymal, and (G) total fat mass was assessed at study end (day 56). (H) Average daily food intake and (I) average daily calorie (kilocalories) intake during PUFA diet exposure (days 29–56). (J) Plasma IL‐1RA levels at study end (day 56). Data are expressed as mean ± SEM or as box and whisker plots and analyzed by one‐ or two‐way ANOVA with Tukey multiple comparisons test and significance calculated using GraphPad Prism version 10.2.2. **** p < 0.0001; *** p < 0.001; ** p < 0.01; and * p < 0.05. DIO, diet‐induced obesity; HFD, high‐fat diet; IL‐1RA, interleukin‐1 receptor antagonist; po, orally; PUFA, <t>polyunsaturated</t> fatty acid; qd, 1 time/day; sc, subcutaneously; tid, 3 times/day.
Polyunsaturated Fatty Acids Pufa 3, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pufa+fatty+acids/pm39168088-81-6-8?v=Millipore
Average 90 stars, based on 1 article reviews
polyunsaturated fatty acids pufa-3 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
standard fatty acids pufa 2  (Millipore)
90
Millipore standard fatty acids pufa 2
Effects of NT‐0796, semaglutide, or combinations in mice with DIO switched to a <t>PUFA</t> diet. Mice with DIO fed a HFD were dosed therapeutically with NT‐0796 (100 mg/kg, po, tid), semaglutide (0.005 mg/kg, sc, q.d), or a combination from day 0 to 28. On day 29, diet was switched to a PUFA diet, and the respective treatment continued (over days 29–56). An additional group of mice served as calorie‐restricted controls, body weight of which were maintained as closely to NT‐0796‐dosed mice as possible by controlling the degree of calorie restriction throughout the experiment. (A) Experimental schematic. (B) Percentage body weight change over time. An overnight fast into day 55 (dashed line) was performed for assessment of further exploratory endpoints. (C) Body weight over time. (D) Perirenal, (E) inguinal, (F) epididymal, and (G) total fat mass was assessed at study end (day 56). (H) Average daily food intake and (I) average daily calorie (kilocalories) intake during PUFA diet exposure (days 29–56). (J) Plasma IL‐1RA levels at study end (day 56). Data are expressed as mean ± SEM or as box and whisker plots and analyzed by one‐ or two‐way ANOVA with Tukey multiple comparisons test and significance calculated using GraphPad Prism version 10.2.2. **** p < 0.0001; *** p < 0.001; ** p < 0.01; and * p < 0.05. DIO, diet‐induced obesity; HFD, high‐fat diet; IL‐1RA, interleukin‐1 receptor antagonist; po, orally; PUFA, <t>polyunsaturated</t> fatty acid; qd, 1 time/day; sc, subcutaneously; tid, 3 times/day.
Standard Fatty Acids Pufa 2, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pufa+fatty+acids/pmc11010829-134-18-24?v=Millipore
Average 90 stars, based on 1 article reviews
standard fatty acids pufa 2 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
polyunsaturated fatty acids (pufa) no.1  (Millipore)
90
Millipore polyunsaturated fatty acids (pufa) no.1
Effects of NT‐0796, semaglutide, or combinations in mice with DIO switched to a <t>PUFA</t> diet. Mice with DIO fed a HFD were dosed therapeutically with NT‐0796 (100 mg/kg, po, tid), semaglutide (0.005 mg/kg, sc, q.d), or a combination from day 0 to 28. On day 29, diet was switched to a PUFA diet, and the respective treatment continued (over days 29–56). An additional group of mice served as calorie‐restricted controls, body weight of which were maintained as closely to NT‐0796‐dosed mice as possible by controlling the degree of calorie restriction throughout the experiment. (A) Experimental schematic. (B) Percentage body weight change over time. An overnight fast into day 55 (dashed line) was performed for assessment of further exploratory endpoints. (C) Body weight over time. (D) Perirenal, (E) inguinal, (F) epididymal, and (G) total fat mass was assessed at study end (day 56). (H) Average daily food intake and (I) average daily calorie (kilocalories) intake during PUFA diet exposure (days 29–56). (J) Plasma IL‐1RA levels at study end (day 56). Data are expressed as mean ± SEM or as box and whisker plots and analyzed by one‐ or two‐way ANOVA with Tukey multiple comparisons test and significance calculated using GraphPad Prism version 10.2.2. **** p < 0.0001; *** p < 0.001; ** p < 0.01; and * p < 0.05. DIO, diet‐induced obesity; HFD, high‐fat diet; IL‐1RA, interleukin‐1 receptor antagonist; po, orally; PUFA, <t>polyunsaturated</t> fatty acid; qd, 1 time/day; sc, subcutaneously; tid, 3 times/day.
Polyunsaturated Fatty Acids (Pufa) No.1, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pufa+fatty+acids/pm38579651-85-29-27?v=Millipore
Average 90 stars, based on 1 article reviews
polyunsaturated fatty acids (pufa) no.1 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Effects of NT‐0796, semaglutide, or combinations in mice with DIO switched to a PUFA diet. Mice with DIO fed a HFD were dosed therapeutically with NT‐0796 (100 mg/kg, po, tid), semaglutide (0.005 mg/kg, sc, q.d), or a combination from day 0 to 28. On day 29, diet was switched to a PUFA diet, and the respective treatment continued (over days 29–56). An additional group of mice served as calorie‐restricted controls, body weight of which were maintained as closely to NT‐0796‐dosed mice as possible by controlling the degree of calorie restriction throughout the experiment. (A) Experimental schematic. (B) Percentage body weight change over time. An overnight fast into day 55 (dashed line) was performed for assessment of further exploratory endpoints. (C) Body weight over time. (D) Perirenal, (E) inguinal, (F) epididymal, and (G) total fat mass was assessed at study end (day 56). (H) Average daily food intake and (I) average daily calorie (kilocalories) intake during PUFA diet exposure (days 29–56). (J) Plasma IL‐1RA levels at study end (day 56). Data are expressed as mean ± SEM or as box and whisker plots and analyzed by one‐ or two‐way ANOVA with Tukey multiple comparisons test and significance calculated using GraphPad Prism version 10.2.2. **** p < 0.0001; *** p < 0.001; ** p < 0.01; and * p < 0.05. DIO, diet‐induced obesity; HFD, high‐fat diet; IL‐1RA, interleukin‐1 receptor antagonist; po, orally; PUFA, polyunsaturated fatty acid; qd, 1 time/day; sc, subcutaneously; tid, 3 times/day.

Journal: Obesity (Silver Spring, Md.)

Article Title: The NLRP3 inhibitor NT ‐0796 enhances and sustains GLP ‐ 1R agonist‐mediated weight loss in a murine diet‐induced obesity model

doi: 10.1002/oby.24305

Figure Lengend Snippet: Effects of NT‐0796, semaglutide, or combinations in mice with DIO switched to a PUFA diet. Mice with DIO fed a HFD were dosed therapeutically with NT‐0796 (100 mg/kg, po, tid), semaglutide (0.005 mg/kg, sc, q.d), or a combination from day 0 to 28. On day 29, diet was switched to a PUFA diet, and the respective treatment continued (over days 29–56). An additional group of mice served as calorie‐restricted controls, body weight of which were maintained as closely to NT‐0796‐dosed mice as possible by controlling the degree of calorie restriction throughout the experiment. (A) Experimental schematic. (B) Percentage body weight change over time. An overnight fast into day 55 (dashed line) was performed for assessment of further exploratory endpoints. (C) Body weight over time. (D) Perirenal, (E) inguinal, (F) epididymal, and (G) total fat mass was assessed at study end (day 56). (H) Average daily food intake and (I) average daily calorie (kilocalories) intake during PUFA diet exposure (days 29–56). (J) Plasma IL‐1RA levels at study end (day 56). Data are expressed as mean ± SEM or as box and whisker plots and analyzed by one‐ or two‐way ANOVA with Tukey multiple comparisons test and significance calculated using GraphPad Prism version 10.2.2. **** p < 0.0001; *** p < 0.001; ** p < 0.01; and * p < 0.05. DIO, diet‐induced obesity; HFD, high‐fat diet; IL‐1RA, interleukin‐1 receptor antagonist; po, orally; PUFA, polyunsaturated fatty acid; qd, 1 time/day; sc, subcutaneously; tid, 3 times/day.

Article Snippet: Additional mouse cohorts were fed a diet enriched in polyunsaturated fatty acids (PUFA; 40% of kilocalories from fat; Dyets, Inc., category #D240510) [ ], which bears greater resemblance to the composition of a typical human diet.

Techniques: Clinical Proteomics, Whisker Assay